TABLE 1.
Characteristics of patients who experienced AKI.
| COVID-19 with DM (n = 168) | All COVID-19 (n = 1,096) | |
|---|---|---|
| Age, years, median (Q1–Q3) | 66 (60–72) | 65 (54–73) |
| Sex, number (%) | ||
| Female | 59 (35.12) | 306 (27.92) |
| Male | 102 (60.71) | 671 (61.22) |
| Not reported | 7 (4.17) | 119 (10.86) |
| Type of reporter, number (%) | ||
| Health professional | 160 (95.24) | 989 (90.24) |
| Non-health professional | 7 (4.17) | 49 (4.47) |
| Unknown | 1 (0.60) | 58 (5.29) |
| Reporting country, number (%) | ||
| First | US/123 (73.21) | US/713 (65.05) |
| Second | FR/10 (5.95) | FR/74 (6.75) |
| Third | BR/9 (5.34) | ES/68 (6.20) |
| Time-to-onset, days, IQR (Q1–Q3) | 2 (1–6) | 3 (1–6) |
| Outcome of event a , number (%) | ||
| Death | 55 (32.74) | 312 (28.47) |
| Life-threatening | 46 (27.38) | 221 (20.16) |
| Hospitalization (initial or prolonged) | 70 (41.67) | 501 (45.71) |
| Disability | 6 (3.58) | 31 (2.83) |
| Required intervention to prevent permanent impairment/damage | 1 (0.60) | 14 (1.28) |
| Congenital anomaly | 0 | 6 (0.55) |
| Other serious events | 111 (66.07) | 689 (62.86) |
| “PS” drugs prescribed for COVID-19 involved, number (%) | ||
| Remdesivir | 109 (64.88) | 444 (40.51) |
| Tocilizumab | 10 (5.95) | 38 (3.47) |
| Hydroxychloroquine | 8 (4.76) | 117 (10.68) |
| Lopinavir/Ritonavir | 0 | 70 (6.39) |
AKI: acute kidney injury; COVID-19: coronavirus disease 2019; DM: diabetes mellitus; IQR: interquartile range; PS: primary suspect; US: united states; FR: france; BR: brazil; ES: espana.
a
A report may have one or more outcomes.